Observational study on medical cannabis use in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study, CAN-RWE, follows 500 pediatric patients aged 3 to 17 years across Canada who have received authorizations for medical cannabis. Over a period of two years, participants will report on various outcome measures including pain, sleep, mood, behavior, and seizure management. Data will be collected at multiple intervals to assess the effectiveness and safety of medical cannabis in managing symptoms related to cancer and other conditions. The study aims to provide real-world evidence on the impact of medical cannabis in pediatric populations.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 3 to 17 years
* have a medical document provided by a prescribing health care practitioner (i.e. physician, nurse practitioner, etc.) for the use of medical cannabis
* medical cannabis is authorized for pain, sleep, mood, behaviour, seizures, cancer or cancer-treatment related symptom management
* ability to respond to electronic questionnaires in English

Exclusion Criteria:

* individuals using cannabis for medical purposes without a medical cannabis authorization from a health care provider
* those only using cannabis recreationally

Where it's running

• U Manitoba
  Winnipeg, Manitoba, Canada Recruiting

Study contacts

• Principal investigator: Sapna Oberoi, MD — University of Manitoba
• Study coordinator: Lauren E Kelly, PhD
• Email: lauren.kelly@umanitoba.ca
• Phone: 2042723149

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating patterns in neurodevelopmental disorders

  This study is trying to find common signs and causes of neurodevelopmental disorders like Autism and Down Syndrome to help with earlier diagnosis and better outcomes for those affected.

  Recruiting Rossignol Medical Center · Phoenix, Arizona · NCT06213090

• RAP-219 long-acting injectable safety and PK study in healthy adults

  This early study tests RAP-219-LAI in healthy adults to see how it behaves in the body and whether it is safe and tolerable.

  Recruiting Phase 1 Rapport Therapeutics Inc. · Adelaide · NCT07923097

• Why People with Epilepsy Get More Infections

  This study tests whether anti-seizure medicines affect immune function and infection risk in people with epilepsy.

  Recruiting University of Aberdeen · Aberdeen · NCT07903168

• Long-Term Epilepsy Outcomes in Children After Perinatal Stroke

  This study looks at how epilepsy progresses in kids who had a stroke before 28 days old to see how their seizures and syndromes evolve over time.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898397

• Understanding brain development in congenital hypothyroidism: comparing affected children, healthy controls, and mild thyroid conditions

  This study tests how brain development in children with congenital hypothyroidism compares to similar children without the condition and to kids with a mild thyroid finding.

  Recruiting at 3 sites Istituto Giannina Gaslini · Genova and 2 other locations · NCT07893522

• Hypothalamus structure and heart autonomic changes in drug-resistant epilepsy

  This study tests whether structural changes in the hypothalamus relate to cardiac autonomic dysfunction in adults with drug-resistant epilepsy.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07888543

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.